{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-006209","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.264178+00:00","generated_at":"2026-06-15T04:54:39.072449+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dermata Therapeutics Q1 cash $8.8M; FDA agrees CMC supports Phase 3 for acne drug DMT310","bullets":["Cash and cash equivalents $8.8M as of March 31, 2023, up from $6.2M at Dec 31, 2022.","Raised $5.0M gross from March 2023 public offering of common stock and warrants.","FDA agreed that CMC procedures are sufficient to initiate Phase 3 studies of DMT310 for moderate-to-severe acne.","R&D expenses $1.2M for Q1 2023, down from $1.6M in Q1 2022; G&A $1.1M vs $1.2M.","Expects cash to fund operations into Q1 2024; awaiting FDA feedback on End of Phase 2 meeting by June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-006209","json":"https://secwatch.observer/filing/0001654954-23-006209.json","markdown":"https://secwatch.observer/filing/0001654954-23-006209.md","text":"https://secwatch.observer/filing/0001654954-23-006209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/0001654954-23-006209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:54:39.072449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"976fd84bd0489862368483a828f83df9e00dabfc","claim":"Dermata Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"reported financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423006209/0001654954-23-006209-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}